The Diagnostic Value Of PSAD Combined With MRS For PSA<10ng/ml Prostate Carcinoma

Objective: Although prostate-specific antigen(PSA)is widely used as a screening tool for prostate cancer in clinical practice,its use as a serum marker still has limitations,including the inability to accurately distinguish between benign and malignant diseases.Therefore,the final diagnosis still requires the prostate Needle biopsy has led to an increase in the number of patients with benign disease or low-risk clinically meaningless prostate cancer that does not require treatment.We combine the use of PSAD and MRS to predict the diagnostic value of patients with PSA<10ng/ml.Materials and methods: This study collected the data of 138 patients with PSA<10ng/ml in the First Affiliated Hospital of Nanchang University and 13-point biopsy of the prostate.According to the PSA level of patients,they were divided into two intervals: PSA<4ng/ml and 4≤PSA<10ng/ml.According to the biopsy report,patients were divided into two subgroups: prostate cancer group and non-cancer group.Use SPSS19.0 software to process the data.The area under the ROC curve was used to analyze and compare the diagnostic efficacy of MRS,PSAD and the combination of the two methods for double positive diagnosis of prostate cancer.Results: Among 138 patients with PSA<10ng/ml,when PSA<4ng/ml,there were 6 cases in the prostate cancer group and 5 cases in the non-cancer group.There was no significant difference in the data between the groups.When 4≤PSA<10ng/ml,there were 51 cases in the prostate cancer group and 76 cases in the non-cancer group.The sensitivity and specificity of using MRS alone to diagnose prostate cancer were 0.84 and 0.72,respectively,and the diagnostic efficiency was 0.60.Using PSAD alone to diagnose prostate cancer,taking the best Youden index,the diagnostic sensitivity and specificity were 0.73 and 0.88,the diagnostic efficiency was 0.64,and the area under the ROC curve was 0.863.MRS combined with PSAD to diagnose prostate cancer,take the best Youden index,the diagnostic sensitivity and specificity are 0.91 and 0.79,respectively,the diagnostic efficiency is 0.72,and the area under the ROC curve is 0.921.Conclusion: When the patient’s PSA is less than 4ng/ml,PSAD fails to show a difference between patients,and MRS can provide limited reference value for the diagnosis of prostate cancer because its specificity is too low.For patients with 4≤PSA<10ng/ml,the diagnostic efficiency of combined PSAD and MRS in double-positive screening for prostate cancer is significantly better than that of single-positive screening,which can effectively increase the positive rate of diagnosing prostate cancer and reduce unnecessary prostate punctures.